Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Large Increase in Short Interest

Aardvark Therapeutics, Inc. (NASDAQ:AARD – Get Free Report) saw a significant increase in short interest in October. As of October 30th, there was short interest totaling 1,038,938 shares, an increase of 87.8% from the October 15th total of 553,262 shares. Based on an average daily volume of 2,760,064 shares, the days-to-cover ratio is presently 0.4 days. Approximately 5.8% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several research firms have issued reports on AARD. UBS Group set a $4.00 target price on Aardvark Therapeutics in a research note on Monday, October 19th. Royal Bank Of Canada set a $2.50 price target on shares of Aardvark Therapeutics in a research report on Friday, October 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Tuesday, September 29th. Oppenheimer downgraded shares of Aardvark Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 26th. Finally, Raymond James Financial reiterated a “market perform” rating on shares of Aardvark Therapeutics in a research note on Friday. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $11.56.

View Our Latest Research Report on Aardvark Therapeutics

Insiders Place Their Bets

In other news, insider Nelson Sun sold 62,000 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00. Following the transaction, the insider owned 35,475 shares of the company’s stock, valued at approximately $183,760.50. This represents a 63.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 17.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aardvark Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Aardvark Therapeutics during the 2nd quarter worth about $1,077,000. Marshall Wace LLP grew its stake in Aardvark Therapeutics by 593.0% during the 3rd quarter. Marshall Wace LLP now owns 132,204 shares of the company’s stock valued at $697,000 after purchasing an additional 113,128 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Aardvark Therapeutics in the first quarter valued at about $267,000. J. Goldman & Co LP acquired a new position in shares of Aardvark Therapeutics in the second quarter valued at about $233,000. Finally, Ieq Capital LLC purchased a new position in shares of Aardvark Therapeutics in the second quarter worth about $221,000.

Aardvark Therapeutics Stock Performance

Aardvark Therapeutics stock opened at $1.33 on Monday. The stock has a 50-day moving average of $3.76 and a two-hundred day moving average of $5.72. Aardvark Therapeutics has a one year low of $0.93 and a one year high of $16.60. The stock has a market cap of $29.10 million, a PE ratio of -0.40 and a beta of 4.39.

Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.19). As a group, sell-side analysts predict that Aardvark Therapeutics will post -3.05 EPS for the current fiscal year.

About Aardvark Therapeutics

(Get Free Report)

Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.

See Also

Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.